Poolbeg Pharma Plc
licences first-in-class broad spectrum RNA-based immunotherapy for respiratory virus infections
SPONSORED ARTICLE
By Elric Langton | 17th January 2022
In my first YouTube venture with Poolbeg Pharma (AIM: POLB), chairman Cathal Friel dropped a few hints there could be a busy period for Poolbeg in the coming weeks. It is an exciting time to be a fully-funded capital light infectious disease pharma company.
1. @ 11m 25s Coming βweeksβ knocking POLB inβ¦